;
Skip to main content
Home > The Daily Extra > Financial News

Chronological Index of : Financial News

 Current Issue
  • FINANCIAL NEWS: Chimerix rises with its bank account

    Chimerix Inc. (NASDAQ:CMRX) gained $1.15 to $31.04 after completing its second big follow-on in 2014. The infectious disease company raised $105.9 million through the sale of 3.65 million shares at $29 in a deal …

    Published on 10/31/2014
  • FINANCIAL NEWS: Imago raises $26.5M series A

    Myeloid malignancy company Imago BioSciences Inc. (San Francisco, Calif.) raised $26.5 million in a series A round led by Clarus Ventures. Frazier Healthcare; Amgen Ventures; and Merck Research Labs Venture Fund also …

    Published on 10/31/2014
  • FINANCIAL NEWS: PolyPid sets IPO terms

    PolyPid Ltd. (Petach Tikva, Israel) amended its proposed IPO on NASDAQ and now plans to sell 1.8 million shares at $10-$12. At $11, PolyPid would raise $20 million and be valued at $103 million. Aegis Capital; MLV; and …

    Published on 10/31/2014
  • FINANCIAL NEWS: Venture tracks

    Clarus Ventures named Barry Gertz a venture partner. He also will become chief medical advisor for Clarus portfolio company Relay Pharmaceuticals Inc., which finances late-stage clinical studies of pharma assets. Gertz …

    Published on 10/31/2014
  • FINANCIAL NEWS: Virobay pulls IPO

    Virobay Inc. (Menlo Park, Calif.) withdrew its proposed IPO on NASDAQ, citing market conditions. Earlier this month, the company amended its offering to sell 3.8 million shares at $12-$14. At $13, it would have raised $…

    Published on 10/31/2014
  • FINANCIAL NEWS: Cortendo pulls Oslo IPO to mull U.S. listing, raises $11.3M

    Cortendo AB (Gothenburg, Sweden) said it will raise SEK 81.5 million ($11.3 million) in a private placement. The company will also drop plans to list on the Oslo Axess exchange and consider a U.S. listing instead.The …

    Published on 10/30/2014
  • FINANCIAL NEWS: FibroGen targeting near-billion dollar valuation

    FibroGen Inc. (San Francisco, Calif.) set terms for its IPO on NASDAQ and plans to sell 7.1 million shares at $16-$19. At $17.50, the company would raise $124.3 million and be valued at $974.3 million. Goldman Sachs; …

    Published on 10/30/2014
  • FINANCIAL NEWS: Incyte jumps on Jakafi trajectory

    Incyte Corp. (NASDAQ:INCY) jumped $6.31 (11%) to $64.18 on Thursday after its 3Q14 earnings beat Street expectations, including a 63% increase in Jakafi ruxolitinib sales compared to 3Q13.Jakafi, sold outside the U.S. …

    Published on 10/30/2014
  • FINANCIAL NEWS: Pacira dinged on Exparel "disruptions"

    Pacira Pharmaceuticals Inc. (NASDAQ:PCRX) fell $14.70 (14%) to $91.11 on Thursday as investors digested comments on the company's earnings call related to a previously announced September warning letter from FDA about …

    Published on 10/30/2014
  • FINANCIAL NEWS: Rhythm withdraws IPO after Actavis deal

    Rhythm Pharmaceuticals Inc. (Boston, Mass.) withdrew its proposed IPO on NASDAQ. Last week, the company received $40 million up front in a deal giving Actavis plc (NYSE:ACT) an option to acquire a Rhythm subsidiary that…

    Published on 10/30/2014
  • FINANCIAL NEWS: Chimerix planning $105M follow-on

    Chimerix Inc. (NASDAQ:CMRX) said it plans to raise about $105 million in a follow-on underwritten by Morgan Stanley; JP Morgan; Cowen; Piper Jaffray; and Stifel, Nicolaus.Chimerix's brincidofovir is in Phase III trials …

    Published on 10/29/2014
  • FINANCIAL NEWS: Regulus raises $75M in follow-on

    Regulus Therapeutics Inc. (NASDAQ:RGLS) wasted little time cashing in on a recent stock surge, as the microRNA company raised $75 million through the sale of 4.4 million shares at $17 in a follow-on underwritten by …

    Published on 10/29/2014
  • FINANCIAL NEWS: Synergy raises $175M in note deal

    Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) raised $175 million through the sale of senior unsecured convertible notes. The notes bear 7.5% interest, mature in 2019 and initially convert at $3.11. Synergy's lead compound…

    Published on 10/29/2014
  • FINANCIAL NEWS: Vanda raises $58M in follow-on

    Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) raised $58 million through the sale of 5 million shares at $11.60 in a follow-on underwritten by Jefferies; Piper Jaffray; JMP Securities; and Canaccord. The neurology company …

    Published on 10/29/2014
  • FINANCIAL NEWS: Diabetes, not CEO, dominates Sanofi earnings

    American depository shares of Sanofi (Euronext:SAN; NYSE:SNY) fell $4.75 to $48.07 in New York on Tuesday as the company revealed that sales in its diabetes franchise would be flat in 2015 primarily because of …

    Published on 10/28/2014
  • FINANCIAL NEWS: SynCore raises $19.4M in Taiwanese IPO

    SynCore Biotechnology Co. Ltd. (GreTai-E:4192) lost NT$15.90 (18%) to NT$70.10 in its first day of trading Tuesday after raising NT$590.6 million ($19.4 million) through the sale of 6.8 million shares at NT$86 in an IPO…

    Published on 10/28/2014
  • FINANCIAL NEWS: Advent closes new fund with L145.5M

    European VC firm Advent Venture Partners closed Advent Life Sciences Fund II with L145.5 million ($234.3 million). The fund came from new and existing LPs, including funds-of-funds, pension funds and family offices.…

    Published on 10/27/2014
  • FINANCIAL NEWS: Amgen boosts guidance ahead of business review

    Amgen Inc. (NASDAQ:AMGN) reported 3Q14 non-GAAP EPS of $2.30 and revenues of $5 billion, which beat the Street and represented 19% and 6% growth over 3Q13, respectively. The company also raised its 2014 guidance on …

    Published on 10/27/2014
  • FINANCIAL NEWS: Syros closes $53M series B for super-enhancers

    Syros Pharmaceuticals Inc. (Watertown, Mass.) raised $53 million in a series B round led by an undisclosed Boston-based public investment firm. Polaris Partners; Aisling Capital; and Redmile Group invested for the first…

    Published on 10/27/2014
  • FINANCIAL NEWS: Angion withdraws IPO

    Angion Biomedica Corp. (Uniondale, N.Y.) withdrew its proposed IPO on NASDAQ, citing market conditions. In June, the company amended its IPO to sell 2.7 million shares at $10-$12. At $11, the company would have raised $…

    Published on 10/24/2014
  • FINANCIAL NEWS: Coherus sets IPO terms

    Biosimilars developer Coherus Biosciences Inc. (Redwood City, Calif.) set terms for its IPO on NASDAQ and plans to sell 6.3 million shares at $12-$15. At $13.50 Coherus would raise $85 million and be valued at $432.7 …

    Published on 10/24/2014
  • FINANCIAL NEWS: Alexion, BioMarin raise 2014 guidance

    Rare disease specialists Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) both raised 2014 guidance in earnings reports on Thursday.Alexion shares added $12.65 to $185.92 after …

    Published on 10/23/2014
  • FINANCIAL NEWS: Erytech raises EUR 30M in follow-on

    Erytech Pharma S.A. (Euronext:ERYP) raised EUR 30 million ($38.2 million) through the sale of 1.2 million shares at EUR 24.50 in a follow-on. U.S. investors provided 68% of the funds.Erytech will use the money to …

    Published on 10/23/2014
  • FINANCIAL NEWS: Probiodrug raises EUR 22.5M in IPO

    Probiodrug AG (Euronext:PBD) raised EUR 22.5 million ($28.7 million) in an IPO through the sale of 1.5 million shares at EUR 15.25 on Euronext Amsterdam, giving the company a market cap of EUR 102.4 million ($130.6 …

    Published on 10/23/2014
  • FINANCIAL NEWS: Quartet raises $17M series A

    Analgesic developer Quartet Medicine (Cambridge, Mass.) raised $17 million in a series A round led by Atlas Venture. Novartis Venture Funds, Pfizer Venture Investment and Partners Innovation Fund also participated. …

    Published on 10/23/2014

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993